RecruitingPhase 1NCT06326463
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
Studying Precursor T-cell acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- St. Jude Children's Research Hospital
- Principal Investigator
- Swati Naik, MBBSSt. Jude
- Intervention
- Fludarabine(drug)
- Enrollment
- 18 target
- Eligibility
- 21 years · All sexes
- Timeline
- 2024 – 2031
Study locations (1)
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06326463 on ClinicalTrials.govOther trials for Precursor T-cell acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07250087Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALLH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06976736A Long Term Follow-up Study of TScan TCR-T ProductsTScan Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT07070323A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte MalignanciesBeijing GoBroad Hospital
- RECRUITINGPHASE2NCT06648889Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic LeukemiaGoethe University
- RECRUITINGEARLY PHASE1NCT06633341Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphomaZhejiang University
- RECRUITINGPHASE2NCT06220487A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLNanfang Hospital, Southern Medical University
- RECRUITINGPHASE2NCT07021677Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"Tata Memorial Centre
- ACTIVE NOT RECRUITINGPHASE2NCT04778579Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to TherapySara V. Latorre
See all trials for Precursor T-cell acute lymphoblastic leukemia →